Results 161 to 170 of about 15,578 (196)

Azole resistance inCandida albicans

Medical Mycology, 1986
An isolate of Candida albicans from a patient with chronic mucocutaneous candidosis who relapsed during ketoconazole treatment was compared with a number of other azole-sensitive and azole-resistant isolates by tests in vitro and in three animal models of vaginal or disseminated infection.
K J, Smith, D W, Warnock, C T, Kennedy, E M, Johnson, V, Hopwood, J, Van Cutsem, H, Vanden Bossche   +6 more
openaire   +2 more sources

Antifungal drug resistance to azoles and polyenes

The Lancet Infectious Diseases, 2002
There is an increased awareness of the morbidity and mortality associated with fungal infections caused by resistant fungi in various groups of patients. Epidemiological studies have identified risk factors associated with antifungal drug resistance.
Mar, Masiá Canuto, Félix, Gutiérrez Rodero   +1 more
openaire   +2 more sources

Azole Resistance in Dermatophytes

Journal of the American Podiatric Medical Association, 2016
Azole antifungal agents (eg, fluconazole and itraconazole) have been widely used to treat superficial fungal infections caused by dermatophytes and, unlike the allylamines (such as terbinafine and naftifine), have been associated with resistance development.
openaire   +1 more source

Azole Antifungal Resistance Today: Focus on Aspergillus

Current Infectious Disease Reports, 2011
Oral triazole therapy is well established for the treatment of invasive aspergillosis (IPA), allergic aspergillosis (ABPA), and chronic pulmonary aspergillosis (CPA), and is often long-term. Resistance to triazole azole antifungal drugs in Aspergillus fumigatus is now a major clinical problem in a number of European locations, in China, Canada and the ...
Bowyer, Paul, Moore, Caroline B., Rautemaa-Richardson, Riina; id_orcid 0000-0002-1071-6040, Denning, David W.; id_orcid 0000-0001-5626-2251, Richardson, Malcolm   +4 more
openaire   +3 more sources

Azole-Resistant Invasive Aspergillosis: Relationship to Agriculture

Current Fungal Infection Reports, 2012
Azole resistance in Aspergillus fumigatus has been increasingly reported particularly over the last decade. Two routes of acquisition are described: selection of resistance during long term azole therapy in the clinical setting, and primary acquisition of resistant isolates from the environment due to the considerable use of azole fungicides in ...
Stensvold, Christen Rune, Jørgensen, Lise Nistrup, Arendrup, Maiken Cavling   +2 more
openaire   +1 more source

Resistance to Azole Drugs in Neurospora crassa

Experimental Mycology, 1995
Neurospora crassa was susceptible to azole drugs: ketoconazole (MIC 1 microgram/ml), fluconazole (MIC 5 micrograms/ml), and SCH39304 (MIC 5 micrograms/ml). Mutants of N. crassa resistant to ketoconazole were selected and genetically characterized. The seven characterized resistance mutations represented at least four genetic loci. Some mutants, but not
openaire   +2 more sources

Azole resistance mechanisms in pathogenic M. furfur.

Antimicrobial agents and chemotherapy, 2021
Malassezia are emerging fungal pathogens causing opportunistic skin and severe systemic infection. Nosocomial outbreaks are associated with azole resistance and understanding of the underlying mechanisms are limited to knowledge from other fungal species. Herein, we identified distinct antifungal susceptibility patterns in 26 Malassezia furfur isolates
Leong, Cheryl, Kit, Joel Chan Wai, Lee, Shi Mun, Lam, Yuen In, Goh, Joleen P Z, Ianiri, Giuseppe, Dawson, Thomas L   +6 more
openaire   +2 more sources

Resistance of yeasts to azole-derivative antifungals

Journal of Antimicrobial Chemotherapy, 1993
There are relatively few antifungal agents available for the treatment of systemic mycoses. The incidence of these infections, particularly among the immunocompromised, has increased significantly in recent years. Amphotericin B, flucytosine and the azole-derivatives--fluconazole, itraconazole and ketoconazole--are the only drugs of value in the ...
openaire   +2 more sources

Fungal Drug Resistance: Azoles

2009
Azole antifungal agents are widely used in the clinical arena to treat a variety of fungal infections. The azoles inhibit fungal lanosterol demethylase, a key fungal enzyme in the ergosterol biosynthetic pathway, leading to an altered membrane physiology and, most frequently, a fungistatic effect.
Jose L. Lopez-Ribot, Thomas F. Patterson
openaire   +1 more source

Molecular aspects of azole antifungal action and resistance

Drug Resistance Updates, 1999
During the past three decades azole compounds have been developed as medical and agricultural agents to combat fungal diseases. During the 1980s they were introduced as orally active compounds in medicine and the number of such azole drugs is likely to expand in the near future.
David, Lamb, Diane, Kelly, Steven, Kelly
openaire   +2 more sources